MannKind's (MNKD) stock surged 73%, driven by its 9% royalty stake in Tyvaso DPI. It has strong liquidity. Click here to see ...

MannKind announced top-level 30-week results from its Phase 4 INHALE-3 study comparing inhaled insulin to traditional ...

MannKind (MNKD) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, MNKD broke through the 20-day moving average, which suggests a short ...

MannKind Corporation (NASDAQ:MNKD) is a U.S.-based biopharmaceutical company focused on developing and commercializing ...

On Friday, MannKind Corp (MNKD) stock saw a decline, ending the day at $6.6 which represents a decrease of $-0.10 or -1.49% from the prior close of $6.7. The stock opened at $6.7 and touched a low of ...

MannKind (MNKD) reported top-level 30-week results from Phase 4 INHALE-3 study, in which additional patients living with type 1 ...

On Monday, MannKind Corp (MNKD) stock saw a modest uptick, ending the day at $6.29 which represents a slight increase of $0.09 or 1.45% from the prior close of $6.2. The stock opened at $6.16 and ...

MannKind Co. (NASDAQ:MNKD – Free Report) – Analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for MannKind in a research report issued on Monday, September 9th.

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative ...

(RTTNews) - MannKind (MNKD) reported top-level 30-week results from Phase 4 INHALE-3 study, in which additional patients living with type 1 diabetes achieved target A1c levels during the extension ...